Mandate

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.

– The listing reflects the transformation we have executed over the past three years. We have built a scalable platform delivering efficiency, solid credit performance and earnings growth versus our Nordic consumer finance peers. Redomiciling to Sweden reduces capital requirements and levels the playing field, said Øyvind Oanes, CEO of Morrow Bank.

Vinge’s team consisted of Emma Stuart-Beck, Elias Bohlin, Henrik Schön, Caroline Krassén, David Flodin, Ebba Gäbel and Felicia Sandén (Financial Services), Rikard Lindahl, Joel Magnusson, Carl Lexenberg and Julia Jönsson (Corporate Public), as well as Siri Blomberg (IT&GDPR), Sam Seddigh, Alice Göransson and Louisa Fagarasan (Employment), Ian Jonsson and Filippa Eriksson (IP), Hedvig Ekdahl and Therese Baltzarsson (Commercial Agreements), Hedvig Merkel (Real Estate), Victor Ericsson, Maria Schultzberg and Vilma Henriksson (Tax), Diana Kanold and Alice Vångell (VDR).

Read the client's press release here and here.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026